Replies to post #168776 on Biotech Values

[ronpopeil]

GILD new data on sofo+RBV in GT3s just presented at adcomm. SVR12 of 85-93% for 6 mod. treatment. Much improved over prior 12 week data.

[DewDiligence]

ABBV/ENTA—New phase-2 study for PK and dose-finding of ABT-493 and ABT-530 individually to support their use in a phase-2 combination study starting in 2014 (#msg-93372516):

http://clinicaltrials.gov/ct2/show/NCT01995071

(This trial's follow-up treatment with ABBV’s first-generation 3-DAA regimen is for ethical reasons.)

H/t @lomu_j and ‘ronpopeil’.